HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Hegseth refuses to rule out US military force against it. Syria is removed by the US Department of State from its State Sponsors of Terrorism list. Nearly 90,000 people are told to evacuate as a wildfire approaches Reno, Nevada. August 25 Ghislaine Maxwell loses her attempt to overturn her sex trafficking conviction. US officials corroborate Trump's claim that the US Navy cleared mines from the Strait of Hormuz Traffic Separation Scheme, saying underwater drones identified more than 100 suspected mines that were subsequently removed or detonated by contractors. Trump says the US will destroy Iranian vessels that lay further mines. Secretary of State Marco Rubio tells allies that the US is not expected to resume major combat operations against Iran "for the time being", with another US official saying this policy is likely to continue until after the midterm elections. August 26 Meta agrees to a $17.1 billion settlement over claims brought by 29 states that its platforms harm children. Palestine Action is designated by the US as a terrorist organization. The FDA approves the new daraxonrasib drug by Revolution Medicines to treat pancreatic cancer. Studies and testing found that patients taking the drug nearly doubled their survival time with fewer side effects. SpaceX and Louisiana governor Jeff Landry co-announce a plan to build a $100 billion spaceport on 125,000 acres (51,000 ha) of land in Vermilion Parish. The US military schedules a trial date for the suspected 9/11 mastermind Khalid Sheik Mohammed in 2028.
=== Oxidation === In general, hydrogen sulfide acts as a reducing agent, as indicated by its ability to reduce sulfur dioxide in the Claus process. Hydrogen sulfide burns in oxygen with a blue flame to form sulfur dioxide (SO2) and water:
== Early life == James Rowley French was born on September 23, 1928, in Pasadena, California, to Mabelle (née Rowley) and James Forrest French. French got his first job in radio as a teenager, on the Pasadena AM station KXLA. French enlisted in the U.S. Army in 1945 and was stationed in allied-occupied Japan, where he worked for the Armed Forces Radio. He attended the Pasadena City College following his discharge.
Sources: en.wikipedia.org
NADPH deficiency can cause a dysfunction in glutathione peroxidase which is an enzyme that converts hydrogen peroxide (a reactive oxygen species) into water. G6PD (glucose-6-phosphate dehydrogenase) deficiency exacerbated by administration of oxidant drugs (e.g., primaquine, dapsone, quinidine) can also result in Heinz bodies. G6PD deficient red cells in combination with high levels of oxidants causes a cross-linking of sulfhydryl groups on globin chains which causes a denaturing and formation of Heinz body precipitates. Heinz bodies can also be found in chronic liver disease. Alpha-thalassemia. Normal adult hemoglobin is composed of two alpha and two beta chains. Alpha thalassemia patients have partial or complete defects in alpha globin production, leading to a relative abundance of beta globin chains in the cell. These excess beta globin chains aggregate to form HbH, which has decreased solubility and precipitates in the red blood cell cytoplasm. This is not direct damage to hemoglobin per se, but rather a perturbation in the quaternary structure of hemoglobin. The presence of Heinz bodies may also be a feature of hyposplenism or asplenia, when a damaged or absent spleen cannot remove these damaged cells from circulation.
==== DC Universe ==== John Stewart / Green Lantern appears in media set in the DC Universe (DCU) franchise, portrayed by Aaron Pierre. This version is a former Green Lantern recruit trained by Hal Jordan whose ring he inherited, albeit powered by a Lantern created by Sinestro and imbued with the power of will and fear.
Roentgenium has no stable or naturally occurring isotopes. Several radioactive isotopes have been synthesized in the laboratory, either by fusion of the nuclei of lighter elements or as intermediate decay products of heavier elements. Nine different isotopes of roentgenium have been reported with atomic masses 272, 274, 278–283, and 286 (283 and 286 unconfirmed), two of which, roentgenium-272 and roentgenium-274, have known but unconfirmed metastable states. All of these decay through alpha decay or spontaneous fission, though 280Rg may also have an electron capture branch.
Scientists calculate that animal genera are going extinct at a rate 35 times faster than expected background rates over the past million years, which they say indicates the planet is experiencing a human-driven sixth mass extinction event and that it is accelerating. A triple-junction solar cell with perovskite-perovskite-silicon subcell configuration is demonstrated with an open-circuit voltage of over 2.8 V, which compares to conventional cells with values ranging between 0.7 V and 0.8 V. 19 September RNA is recovered from a Tasmanian tiger, or thylacine, the first isolation and decoding of such molecules from an extinct species. The iconic genus Rafflesia, which includes the world's largest flower, is reported to be at risk of extinction due to habitat loss. 20 September Researchers demonstrate that measuring blood pressure in the standing position yields enhanced diagnosis of hypertension. Archaeologists in Zambia find the world's oldest wooden structure, dating back 476,000 years. 21 September – Carbon is reported to be present in the subterranean ocean of Europa, based on observations by the James Webb Space Telescope. 22 September – Astronomers report studies of the TRAPPIST-1 b exoplanet, finding no signs of an atmosphere, and commenting that the "planet could be a bare rock, have clouds high in the atmosphere or have a very heavy molecule like carbon dioxide that makes the atmosphere too small to detect."
Sources: en.wikipedia.org
=== Modified Miller–Urey experiments === Much work has been done since the 1950s toward understanding how Miller–Urey chemistry behaves in various environmental settings. Different atmospheric compositions. In 1983, testing different atmospheric compositions, Miller and another researcher repeated experiments with varying proportions of H2, H2O, N2, CO2 or CH4, and sometimes NH3. They found that the presence or absence of NH3 in the mixture did not significantly impact amino acid yield, as NH3 was generated from N2 during the spark discharge. Additionally, CH4 proved to be one of the most important atmospheric ingredients for high yields, likely due to its role in HCN formation. Much lower yields were obtained with more oxidized carbon species in place of CH4, but similar yields could be reached with a high H2/CO2 ratio. Thus, Miller–Urey reactions work in atmospheres of other compositions as well, depending on the ratio of reducing and oxidizing gases. Role of nitrites and calcium carbonate. More recently, Jeffrey Bada and H. James Cleaves, graduate students of Miller, hypothesized that the production of nitrites, which destroy amino acids, in CO2 and N2-rich atmospheres may explain low amino acids yields. In a Miller–Urey setup with a less-reducing (CO2 + N2 + H2O) atmosphere, when they added calcium carbonate to buffer the aqueous solution and ascorbic acid to inhibit oxidation, yields of amino acids greatly increased, demonstrating that amino acids can still be formed in more neutral atmospheres under the right geochemical conditions.
In medicine, collateralization, also vessel collateralization and blood vessel collateralization, is the growth of a blood vessel or several blood vessels that serve the same end organ or vascular bed as another blood vessel that cannot adequately supply that end organ or vascular bed sufficiently. Coronary collateralization is considered a normal response to hypoxia and may be induced, under some circumstances, by exercise. It is considered to be protective. Collateral or anastomotic blood vessels also exist even when blood supply is adequate to an area, and these blood vessels are often taken advantage of in surgery. Some notable areas where this occurs include the abdomen, rectum, knee, shoulder, and head.
Formation of a secondary structure is the first step in the folding process that a protein takes to assume its native structure. Characteristic of secondary structure are the structures known as alpha helices and beta sheets that fold rapidly because they are stabilized by intramolecular hydrogen bonds, as was first characterized by Linus Pauling. Formation of intramolecular hydrogen bonds provides another important contribution to protein stability. α-helices are formed by hydrogen bonding of the backbone to form a spiral shape (refer to figure on the right). The β pleated sheet is a structure that forms with the backbone bending over itself to form the hydrogen bonds (as displayed in the figure to the left). The hydrogen bonds are between the amide hydrogen and carbonyl oxygen of the peptide bond. There exists anti-parallel β pleated sheets and parallel β pleated sheets where the stability of the hydrogen bonds is stronger in the anti-parallel β sheet as it hydrogen bonds with the ideal 180 degree angle compared to the slanted hydrogen bonds formed by parallel sheets.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.